



(51) International Patent Classification:

A61K 47/68 (2017.01) A61P 35/00 (2006.01)
A61K 47/69 (2017.01)

(21) International Application Number:

PCT/CN2024/087405

(22) International Filing Date:

12 April 2024 (12.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/088101

13 April 2023 (13.04.2023)

CN

(71) Applicant: **GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD.** [CN/CN]; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: **SUN, Yajun**; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **SONG, Paul H.**; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN). **QIN, Gang**; 5th Floor, Building D, No. 398, Ruoshui Rd., Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.**; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng District, Beijing 100013 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF

(57) Abstract: The present disclosure relates to a combination of antibody-drug conjugate and anti-PD-1 antibody, and use thereof.




Figure 11

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*